Table 1.
Patient’s characteristics.
| Patients number (274) | Characteristics | Number (%) |
|---|---|---|
| Gender | Female Male |
171 (62) 103 (38) |
| Age at diagnosis | ≥50 yrs <50 yrs |
247 (90) 27 (10) |
| Smoking status | Yes No/Unknown |
182 (66) 92 (34) |
| Performance status | 0–1 <1 Missing |
222 (91) 21 (9) 31 |
| EGFR mutation | 18/20 19 21 Missing |
22 (9) 144 (57) 85 (34) 23 |
| EGFR mutation T790M | Yes No Missing |
28 (55) 23 (45) 51 |
| Number of metastatic sites | Only bone mets 2 mets ≥3 |
12 (4) 36 (13) 226 (83) |
| Synchronous mets | Yes No |
203 (74) 71 (26) |
| Visceral mets | Yes No |
262 (96) 12 (4) |
| Lung mets | Yes No |
162 (59) 112 (41) |
| Liver mets | Yes No |
62 (23) 212 (77) |
| Lymph nodes | Yes No |
205 (75) 68 (25) |
| CNS mets | Yes No |
105 (38) 169 (62) |
| Adrenal mets | Yes No |
41 (15) 233 (85) |
| Comorbidities | Yes No |
133 (49) 141 (51) |
| Bone mets | Osteolytic/Mixed Osteoblastic Missing |
163 (66) 84 (34) 27 |
| Number of bone mets sites | 1–2 3–4 5–10 Missing |
125 (47) 83 (31) 57 (22) 9 |
| Hemoglobin | ≤12 g/dl (women); ≤14 (men) Normal value Missing |
85 (50) 84 (50) 105 |
| ALP | ≥220 U/I Normal value Missing |
32 (26) 89 (74) 153 |
| LDH | ≥300 U/I Normal value Missing |
70 (53) 63 (47) 141 |
| TKI | Gefitinib Erlotinib Afatinib Osimertinib |
184 (67) 43 (16) 46 (17) 1 (0.4) |
Clinical and pathological characteristics of patients with bone metastatic EGFR-mutated lung adenocarcinoma. (EGFR, epidermal growth factor receptor; CNS, central nervous system; ALP, alkaline phosphatase; LDH, lactate dehydrogenase; TKI, tyrosine kinase inhibitor).